Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Disappointingly, the sensitivity and specificity of <strong><a href="https://www.smartkarma.com/entities/narhex-life-sciences-ltd" target="_blank" data-smartkarma-citation="entities:9728:1" rel="noopener">ResApp Health (RAP AU)</a></strong>'s cough trial were significantly lower than its March pilot study.</li>
<li>As such, the Scheme Consideration from <strong><a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US)</a> </strong>will be A$0.146/share, which is still a 62.2% premium to the undisturbed price.</li>
<li>Trading super wide to terms after short-term punters kicked out. </li>
</ul>


Disappointingly, the sensitivity and specificity of ResApp Health (RAP AU)'s cough trial were significantly lower than its March pilot study.
As such, the Scheme Consideration from Pfizer Inc (PFE US) will be A$0.146/share, which is still a 62.2% premium to the undisturbed price.
Trading super wide to terms after short-term punters kicked out. 


ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails

Resapp Health

ResApp (RAP AU): Low-End Pfizer Offer As Cough Trial Fails